Moderna, Merck personalized mRNA cancer vaccine cuts melanoma recurrence in Phase 2 INTerpath-001
The individualized mRNA vaccine given with Keytruda showed improved recurrence-free survival in melanoma, the most advanced readout for the platform outside Cov
STAT · +14 outlets
Inovio's DNA immunotherapy Voceryq wins FDA accelerated approval for recurrent respiratory papillomatosis
Voceryq (INO-3107) becomes the first DNA-based immunotherapy cleared in the US, targeting a rare HPV-driven airway disease; Precigen shares fell 27% after hours
HCPLive · +12 outlets
UK researchers hail personalized melanoma vaccine results as major step forward
Encompasses the melanoma, pancreatic, and kidney cancer mRNA vaccine readouts and expert commentary on the platform's potential.
The Institute of Cancer Research (ICR) · +11 outlets
Japan performs world's first stem cell transplant for Parkinson's disease in patient
The treatment uses induced pluripotent stem cell-derived dopamine neurons; separately, Aspen Neuroscience raised a $141 million IPO for its own Parkinson's cell
Biopharmadive · +9 outlets
Pancreatic cancer mRNA vaccine activates immune response in 99% of patients in early trial
Early data suggest the personalized vaccine triggers strong immune responses in pancreatic cancer, a notoriously hard-to-treat disease.
Vietnam.vn · +13 outlets
Lilly's experimental weight-loss drug retatrutide beats Ozempic in head-to-head trial
Retatrutide, which targets three hormone receptors, is among the most potent obesity drugs in development.
Indian Pharma Post · +14 outlets
Pelthos Therapeutics to merge with Castle Creek Biosciences in rare skin-disease deal; shares fall 35%
The combined company will pursue a rare dermatology therapy, with up to $300 million in milestone payments tied to the transaction.
The Pharma Letter · +8 outlets
FDA proposal could let one approval cover multiple personalized gene-editing treatments for rare diseases
The framework aims to streamline the regulatory path for bespoke CRISPR medicines that each treat very small patient populations.
Medical Daily · +14 outlets
Iovance shares crash after surprise lung cancer trial twist; adds biomarker selection to lifileucel study
The cell therapy developer is refining patient selection for its tumor-infiltrating lymphocyte therapy in lung cancer after the setback.
The Clinical Trial Vanguard · +2 outlets
Acumen Pharmaceuticals scraps sole asset after Alzheimer's failure, stock plunges 80%
The company abandoned its lead Alzheimer's antibody candidate and will seek strategic alternatives.
BioSpace · +1 outlets
FDA proposes withdrawing Tavneos approval in the US
The agency moved to pull the vasculitis drug from the market, a rare step against an approved medicine.
UA.NEWS · +9 outlets
Gilead discloses partial clinical hold on two CAR-T cell therapy trials
The partial hold pauses parts of the company's CAR-T programs pending further review.
Fierce Biotech · +1 outlets
AstraZeneca launches $1.5B-a-year cost-cutting program, trims early prostate cancer pipeline
The three-year savings plan will be reinvested in R&D while the company prunes early-stage prostate cancer assets.
STAT · +9 outlets
FDA enforces long-awaited clinical trial result transparency rules
The move compels sponsors to post trial results, addressing years of complaints about missing data.
Undark Magazine · +2 outlets
Samsung Bioepis seeks US approval for Keytruda biosimilar SB27 across 18 cancer indications
The filing targets the world's top-selling cancer drug as biosimilar competition to Keytruda approaches.
헬스조선 · +5 outlets
Merck to raise next-decade revenue forecast on optimism about new drugs
The pharma giant is betting on its pipeline to offset coming patent expirations on key products.
pharma.economictimes.indiatimes.com · +2 outlets
Dren Bio raises $350M to push rare blood cancer therapy toward market
The financing will fund late-stage development of the company's bispecific antibody for a rare blood cancer.
BioXconomy
Gilead, AstraZeneca and others in focus as Q3 earnings roundup highlights Lilly momentum, Novartis rebound, GSK caution
Lilly's results eased GLP-1 pricing concerns while Novartis and GSK navigated mixed quarters.
Biopharmadive